CA2563367A1 - Novel compositions and methods in cancer - Google Patents

Novel compositions and methods in cancer Download PDF

Info

Publication number
CA2563367A1
CA2563367A1 CA002563367A CA2563367A CA2563367A1 CA 2563367 A1 CA2563367 A1 CA 2563367A1 CA 002563367 A CA002563367 A CA 002563367A CA 2563367 A CA2563367 A CA 2563367A CA 2563367 A1 CA2563367 A1 CA 2563367A1
Authority
CA
Canada
Prior art keywords
protein
polypeptide
expression
polynucleotide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002563367A
Other languages
English (en)
French (fr)
Inventor
David W. Morris
Marc S. Malandro
Albert Lai
Christin Tse
Ali Fattaey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sagres Discovery Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2563367A1 publication Critical patent/CA2563367A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002563367A 2004-04-30 2005-05-02 Novel compositions and methods in cancer Abandoned CA2563367A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/836,956 2004-04-30
US10/836,956 US20090215711A1 (en) 2004-04-30 2004-04-30 Novel compositions and methods in cancer
PCT/US2005/014965 WO2005107396A2 (en) 2004-04-30 2005-05-02 Novel compositions and methods in cancer

Publications (1)

Publication Number Publication Date
CA2563367A1 true CA2563367A1 (en) 2005-11-17

Family

ID=35320645

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002563367A Abandoned CA2563367A1 (en) 2004-04-30 2005-05-02 Novel compositions and methods in cancer

Country Status (6)

Country Link
US (2) US20090215711A1 (enExample)
EP (1) EP1747228A4 (enExample)
JP (1) JP2009523004A (enExample)
AU (1) AU2005240070A1 (enExample)
CA (1) CA2563367A1 (enExample)
WO (1) WO2005107396A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862803A1 (en) * 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
CA2705509A1 (en) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-gpr49 antibody
EP2172477A1 (en) 2008-10-06 2010-04-07 Atlas Antibodies AB Epitopes derived from SATB2 and uses thereof
AU2009331178A1 (en) 2008-12-26 2011-08-11 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-LGR7 antibody
US9107892B2 (en) 2010-10-28 2015-08-18 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of a novel retrovirus in patients with benign prostatic hyperplasia
FR2984363B1 (fr) * 2011-12-20 2017-11-24 Biomerieux Sa Procede pour le diagnostic ou le pronostic in vitro du cancer du sein
WO2017062750A1 (en) * 2015-10-09 2017-04-13 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating stargardt's disease and other ocular disorders
WO2020219543A1 (en) * 2019-04-26 2020-10-29 The Regents Of The University Of California Cells for enhanced production of adeno-associated virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
AU2001263408A1 (en) * 2000-05-23 2001-12-03 The Rockefeller University C1 bacteriophage lytic system
WO2002068633A2 (en) * 2000-11-22 2002-09-06 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
EP2093233A1 (en) * 2002-03-21 2009-08-26 Sagres Discovery, Inc. Novel compositions and methods in cancer
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
US7276596B2 (en) * 2003-02-25 2007-10-02 Pioneer Hi-Bred International, Inc. Promoter from maize invertase inhibitor gene

Also Published As

Publication number Publication date
JP2009523004A (ja) 2009-06-18
EP1747228A2 (en) 2007-01-31
EP1747228A4 (en) 2008-05-28
AU2005240070A1 (en) 2005-11-17
US20090215711A1 (en) 2009-08-27
WO2005107396A3 (en) 2006-03-23
US20070042385A1 (en) 2007-02-22
WO2005107396A2 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
US7332281B2 (en) Therapeutic targets in cancer
EP2196474A2 (en) Therapeutic targets in cancer
US20060194265A1 (en) Novel therapeutic targets in cancer
US20080039413A1 (en) Novel compositions and methods in cancer
US20050202442A1 (en) Novel therapeutic targets in cancer
US20080274467A1 (en) Novel Therapeutic Targets in Cancer
US20070042385A1 (en) Novel compositions and methods in cancer
US7767387B2 (en) Therapeutic targets in cancer
EP2204376A2 (en) Novel therapeutic targets in cancer
EP2058408A2 (en) Therapeutic GPCR targets in cancer
US20090214542A1 (en) Novel therapeutic targets in cancer
CA2513137A1 (en) Novel compositions and methods in cancer
US20070281896A1 (en) Novel compositions and methods in cancer
US20040180344A1 (en) Novel therapeutic targets in cancer
US20070218071A1 (en) Novel therapeutic targets in cancer
CA2572509A1 (en) Novel compositions and methods in cancer

Legal Events

Date Code Title Description
FZDE Dead